Denne side blev automatisk oversat, og nøjagtigheden af oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Cytogenetiske undersøgelser i akut leukæmi og myelomatose

30. juli 2024 opdateret af: Alliance for Clinical Trials in Oncology

Cytogenetiske undersøgelser i akut leukæmi og multipelt myelom: ledsager til CALGB-behandlingsundersøgelser for tidligere ubehandlede patienter med akut myeloid leukæmi (AML), akut lymfoblastisk leukæmi (ALL), myelodysplastisk syndrom (MDS) eller multipelt myelom (MM)

Kromosomanalyse eller undersøgelse af genetiske forskelle hos patienter, der tidligere ikke har været behandlet med AML, ALL, MDS eller MM, kan være nyttige ved diagnosticering og klassificering af sygdom. Det kan også forbedre evnen til at forudsige sygdomsforløbet og valg af terapi. Institutioner skal enten have en Alliance-godkendt cytogenetiker eller en aftale fra et Alliance-godkendt cytogenetiklaboratorium, der er godkendt af Alliancen, for at tilmelde en patient på CALGB 8461. Listen over Alliance-godkendte institutionelle cytogenetikere er offentliggjort på webstedet Alliance for Clinical Trials in Oncology.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Genetisk: cytogenetisk analyse

Undersøgelsestype

Observationel

Tilmelding (Anslået)

9000

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

Forenede Stater
- California
  - La Jolla, California, Forenede Stater, 92093-0658
    - Rebecca and John Moores UCSD Cancer Center
  - Mountain View, California, Forenede Stater, 94040
    - Camino Medical Group - Treatment Center
  - San Diego, California, Forenede Stater, 92134
    - Naval Medical Center - San Diego
  - San Diego, California, Forenede Stater, 92108
    - Kaiser Permanente Medical Office -Vandever Medical Office
  - San Francisco, California, Forenede Stater, 94115
    - UCSF Helen Diller Family Comprehensive Cancer Center
- Delaware
  - Lewes, Delaware, Forenede Stater, 19958
    - Tunnell Cancer Center at Beebe Medical Center
  - Newark, Delaware, Forenede Stater, 19713
    - CCOP - Christiana Care Health Services
- District of Columbia
  - Washington, District of Columbia, Forenede Stater, 20007
    - Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
  - Washington, District of Columbia, Forenede Stater, 20010
    - Washington Cancer Institute at Washington Hospital Center
- Florida
  - Fort Lauderdale, Florida, Forenede Stater, 33308
    - Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital
  - Jupiter, Florida, Forenede Stater, 33458
    - Ella Milbank Foshay Cancer Center at Jupiter Medical Center
  - Miami Beach, Florida, Forenede Stater, 33140
    - CCOP - Mount Sinai Medical Center
- Illinois
  - Bloomington, Illinois, Forenede Stater, 61701
    - Illinois CancerCare - Bloomington
  - Bloomington, Illinois, Forenede Stater, 61701
    - St. Joseph Medical Center
  - Canton, Illinois, Forenede Stater, 61520
    - Illinois CancerCare - Canton
  - Canton, Illinois, Forenede Stater, 61520
    - Graham Hospital
  - Carthage, Illinois, Forenede Stater, 62321
    - Memorial Hospital
  - Carthage, Illinois, Forenede Stater, 62321
    - Illinois CancerCare - Carthage
  - Chicago, Illinois, Forenede Stater, 60637-1470
    - University of Chicago Cancer Research Center
  - Chicago, Illinois, Forenede Stater, 60612-7243
    - University of Illinois Cancer Center
  - Eureka, Illinois, Forenede Stater, 61530
    - Illinois CancerCare - Eureka
  - Eureka, Illinois, Forenede Stater, 61530
    - Eureka Community Hospital
  - Evanston, Illinois, Forenede Stater, 60201-1781
    - Evanston Hospital
  - Galesburg, Illinois, Forenede Stater, 61401
    - Illinois CancerCare - Galesburg
  - Galesburg, Illinois, Forenede Stater, 61401
    - Galesburg Clinic, PC
  - Havana, Illinois, Forenede Stater, 62644
    - Mason District Hospital
  - Havana, Illinois, Forenede Stater, 62644
    - Illinois CancerCare - Havana
  - Kewanee, Illinois, Forenede Stater, 61443
    - Illinois CancerCare - Kewanee Clinic
  - Macomb, Illinois, Forenede Stater, 61455
    - Illinois CancerCare - Macomb
  - Macomb, Illinois, Forenede Stater, 61455
    - Mcdonough District Hospital
  - Monmouth, Illinois, Forenede Stater, 61462
    - Illinois CancerCare - Monmouth
  - Monmouth, Illinois, Forenede Stater, 61462
    - OSF Holy Family Medical Center
  - Normal, Illinois, Forenede Stater, 61761
    - Bromenn Regional Medical Center
  - Normal, Illinois, Forenede Stater, 61761
    - Community Cancer Center
  - Normal, Illinois, Forenede Stater, 61761
    - Illinois CancerCare - Community Cancer Center
  - Ottawa, Illinois, Forenede Stater, 61350
    - Community Hospital of Ottawa
  - Ottawa, Illinois, Forenede Stater, 61350
    - Oncology Hematology Associates of Central Illinois, PC - Ottawa
  - Pekin, Illinois, Forenede Stater, 61554
    - Cancer Treatment Center at Pekin Hospital
  - Pekin, Illinois, Forenede Stater, 61603
    - Illinois CancerCare - Pekin
  - Peoria, Illinois, Forenede Stater, 61636
    - Methodist Medical Center of Illinois
  - Peoria, Illinois, Forenede Stater, 61614
    - Proctor Hospital
  - Peoria, Illinois, Forenede Stater, 61637
    - OSF St. Francis Medical Center
  - Peoria, Illinois, Forenede Stater, 61615
    - CCOP - Illinois Oncology Research Association
  - Peoria, Illinois, Forenede Stater, 61615
    - Oncology Hematology Associates of Central Illinois, PC - Peoria
  - Peru, Illinois, Forenede Stater, 61354
    - Illinois CancerCare - Peru
  - Peru, Illinois, Forenede Stater, 61354
    - Illinois Valley Community Hospital
  - Princeton, Illinois, Forenede Stater, 61356
    - Perry Memorial Hospital
  - Princeton, Illinois, Forenede Stater, 61356
    - Illinois CancerCare - Princeton
  - Spring Valley, Illinois, Forenede Stater, 61362
    - Illinois CancerCare - Spring Valley
- Indiana
  - Fort Wayne, Indiana, Forenede Stater, 46845
    - Fort Wayne Medical Oncology and Hematology
- Iowa
  - Cedar Rapids, Iowa, Forenede Stater, 52402
    - St. Luke's Hospital
  - Cedar Rapids, Iowa, Forenede Stater, 52403
    - Mercy Regional Cancer Center at Mercy Medical Center
  - Cedar Rapids, Iowa, Forenede Stater, 52402
    - Iowa Blood and Cancer Care
  - Iowa City, Iowa, Forenede Stater, 52242-1002
    - Holden Comprehensive Cancer Center at University of Iowa
- Kansas
  - Overland Park, Kansas, Forenede Stater, 66209
    - Menorah Medical Center
  - Overland Park, Kansas, Forenede Stater, 66213
    - Saint Luke's Hospital - South
  - Prairie Village, Kansas, Forenede Stater, 66208
    - CCOP - Kansas City
- Maine
  - Augusta, Maine, Forenede Stater, 04330
    - Harold Alfond Center for Cancer Care
  - Bangor, Maine, Forenede Stater, 04401
    - CancerCare of Maine at Eastern Maine Medical Center
  - Scarborough, Maine, Forenede Stater, 04074
    - Maine Center for Cancer Medicine and Blood Disorders - Scarborough
- Maryland
  - Baltimore, Maryland, Forenede Stater, 21201
    - Greenebaum Cancer Center at University of Maryland Medical Center
  - Baltimore, Maryland, Forenede Stater, 21237
    - Harry and Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center
  - Elkton, Maryland, Forenede Stater, 21921
    - Union Hospital of Cecil County
- Massachusetts
  - Boston, Massachusetts, Forenede Stater, 02114
    - Massachusetts General Hospital
  - Boston, Massachusetts, Forenede Stater, 02115
    - Dana-Farber/Brigham and Women's Cancer Center
  - Boston, Massachusetts, Forenede Stater, 02115
    - Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
- Michigan
  - Battle Creek, Michigan, Forenede Stater, 49017
    - Battle Creek Health System Cancer Care Center
  - Big Rapids, Michigan, Forenede Stater, 49307
    - Mecosta County Medical Center
  - Grand Rapids, Michigan, Forenede Stater, 49503
    - Butterworth Hospital at Spectrum Health
  - Grand Rapids, Michigan, Forenede Stater, 49503
    - CCOP - Grand Rapids
  - Grand Rapids, Michigan, Forenede Stater, 49503
    - Lacks Cancer Center at Saint Mary's Health Care
  - Muskegon, Michigan, Forenede Stater, 49444
    - Mercy General Health Partners
  - Reed City, Michigan, Forenede Stater, 49677
    - Spectrum Health Reed City Hospital
  - Traverse City, Michigan, Forenede Stater, 49684
    - Munson Medical Center
- Minnesota
  - Duluth, Minnesota, Forenede Stater, 55805
    - St. Luke's Hospital Cancer Care Center
  - Minneapolis, Minnesota, Forenede Stater, 55417
    - Veterans Affairs Medical Center - Minneapolis
  - Minneapolis, Minnesota, Forenede Stater, 55455
    - Masonic Cancer Center at University of Minnesota
- Missouri
  - Cape Girardeau, Missouri, Forenede Stater, 63703
    - Southeast Cancer Center
  - Columbia, Missouri, Forenede Stater, 65203
    - Ellis Fischel Cancer Center at University of Missouri - Columbia
  - Jefferson City, Missouri, Forenede Stater, 65109
    - Goldschmidt Cancer Center
  - Kansas City, Missouri, Forenede Stater, 64116
    - North Kansas City Hospital
  - Kansas City, Missouri, Forenede Stater, 64132
    - Research Medical Center
  - Kansas City, Missouri, Forenede Stater, 64111
    - Saint Luke's Cancer Institute at Saint Luke's Hospital
  - Kansas City, Missouri, Forenede Stater, 64118
    - Heartland Hematology Oncology Associates, Incorporated
  - Lee's Summit, Missouri, Forenede Stater, 64086
    - Saint Luke's East - Lee's Summit
  - Liberty, Missouri, Forenede Stater, 64068
    - Parvin Radiation Oncology
  - Saint Joseph, Missouri, Forenede Stater, 64506
    - Heartland Regional Medical Center
  - Saint Joseph, Missouri, Forenede Stater, 64507
    - Saint Joseph Oncology, Incorporated
  - Saint Louis, Missouri, Forenede Stater, 63131
    - Missouri Baptist Cancer Center
  - Saint Louis, Missouri, Forenede Stater, 63110
    - Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
- Nebraska
  - Grand Island, Nebraska, Forenede Stater, 68803
    - Saint Francis Cancer Treatment Center at Saint Francis Memorial Health Center
  - North Platte, Nebraska, Forenede Stater, 69103
    - Callahan Cancer Center at Great Plains Regional Medical Center
  - Omaha, Nebraska, Forenede Stater, 68198-6805
    - UNMC Eppley Cancer Center at the University of Nebraska Medical Center
- Nevada
  - Las Vegas, Nevada, Forenede Stater, 89109
    - Sunrise Hospital and Medical Center
  - Las Vegas, Nevada, Forenede Stater, 89102
    - University Medical Center of Southern Nevada
  - Las Vegas, Nevada, Forenede Stater, 89106
    - CCOP - Nevada Cancer Research Foundation
- New Hampshire
  - Lebanon, New Hampshire, Forenede Stater, 03756-0002
    - Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
- New Jersey
  - Voorhees, New Jersey, Forenede Stater, 08043
    - Cancer Institute of New Jersey at Cooper - Voorhees
- New York
  - Buffalo, New York, Forenede Stater, 14263-0001
    - Roswell Park Cancer Institute
  - East Syracuse, New York, Forenede Stater, 13057
    - CCOP - Hematology-Oncology Associates of Central New York
  - Glens Falls, New York, Forenede Stater, 12801
    - Charles R. Wood Cancer Center at Glens Falls Hospital
  - Lake Success, New York, Forenede Stater, 11042
    - Monter Cancer Center of the North Shore-LIJ Health System
  - Manhasset, New York, Forenede Stater, 11030
    - CCOP - North Shore University Hospital
  - Manhasset, New York, Forenede Stater, 11030
    - Don Monti Comprehensive Cancer Center at North Shore University Hospital
  - New Hyde Park, New York, Forenede Stater, 11040
    - Long Island Jewish Medical Center
  - New York, New York, Forenede Stater, 10021
    - New York Weill Cornell Cancer Center at Cornell University
  - New York, New York, Forenede Stater, 10029
    - Mount Sinai Medical Center
  - Syracuse, New York, Forenede Stater, 13210
    - SUNY Upstate Medical University Hospital
- North Carolina
  - Asheville, North Carolina, Forenede Stater, 28801
    - Mission Hospitals - Memorial Campus
  - Chapel Hill, North Carolina, Forenede Stater, 27599-7295
    - Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
  - Charlotte, North Carolina, Forenede Stater, 28233-3549
    - Presbyterian Cancer Center at Presbyterian Hospital
  - Concord, North Carolina, Forenede Stater, 28025
    - Batte Cancer Center at Northeast Medical Center
  - Durham, North Carolina, Forenede Stater, 27710
    - Duke Cancer Institute
  - Goldsboro, North Carolina, Forenede Stater, 27534
    - Wayne Memorial Hospital, Incorporated
  - Greenville, North Carolina, Forenede Stater, 27834
    - Leo W. Jenkins Cancer Center at ECU Medical School
  - Hendersonville, North Carolina, Forenede Stater, 28791
    - Pardee Memorial Hospital
  - Kinston, North Carolina, Forenede Stater, 28501
    - Kinston Medical Specialists
  - Winston-Salem, North Carolina, Forenede Stater, 27157-1096
    - Wake Forest University Comprehensive Cancer Center
  - Winston-Salem, North Carolina, Forenede Stater, 27103
    - Forsyth Regional Cancer Center at Forsyth Medical Center
- Ohio
  - Columbus, Ohio, Forenede Stater, 43210-1240
    - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
- Oklahoma
  - Oklahoma City, Oklahoma, Forenede Stater, 73104
    - Oklahoma University Cancer Institute
- Pennsylvania
  - Pittsburgh, Pennsylvania, Forenede Stater, 15224-1791
    - Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
- Rhode Island
  - Providence, Rhode Island, Forenede Stater, 02906
    - Miriam Hospital
  - Providence, Rhode Island, Forenede Stater, 02903
    - Rhode Island Hospital Comprehensive Cancer Center
- South Carolina
  - Florence, South Carolina, Forenede Stater, 29501
    - McLeod Regional Medical Center
  - Greenville, South Carolina, Forenede Stater, 29615
    - CCOP - Greenville
  - Greenville, South Carolina, Forenede Stater, 29605
    - Greenville Hospital Cancer Center
  - Greenville, South Carolina, Forenede Stater, 29615
    - Cancer Centers of the Carolinas - Eastside
  - Greenville, South Carolina, Forenede Stater, 29605
    - Cancer Centers of the Carolinas - Faris Road
  - Greenville, South Carolina, Forenede Stater, 29605
    - Cancer Centers of the Carolinas - Grove Commons
  - Greer, South Carolina, Forenede Stater, 29650
    - Cancer Centers of the Carolinas - Greer Medical Oncology
  - Seneca, South Carolina, Forenede Stater, 29672
    - Cancer Centers of the Carolinas - Seneca
  - Spartanburg, South Carolina, Forenede Stater, 29307
    - Cancer Centers of the Carolinas - Spartanburg
- Vermont
  - Berlin, Vermont, Forenede Stater, 05602
    - Mountainview Medical
  - Burlington, Vermont, Forenede Stater, 05401
    - Fletcher Allen Health Care - University Health Center Campus
- Virginia
  - Danville, Virginia, Forenede Stater, 24541
    - Danville Regional Medical Center
  - Richmond, Virginia, Forenede Stater, 23298-0037
    - Virginia Commonwealth University Massey Cancer Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Patientpopulation fra det kliniske onkologiske forskningsmiljø, herunder akademiske institutioner, hospitaler og klinikker.

Beskrivelse

Patienter fra tillægsmidler er berettigede, hvis hovedmedlemscytogenetiklaboratoriet har indvilliget i at behandle prøver fra det pågældende hjælpestof.
Inden for en måned efter registrering på CALGB 8461 skal du registrere dig til et CALGB-behandlingsstudie for tidligere ubehandlede AML-, ALL-, MDS- eller MM-patienter.
Samtidig med registrering på CALGB 8461, registrer patienter inden for det kontinentale USA på CALGB 9665 (LTB).

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Antal grupper/kohorter

Kohorter og interventioner

Gruppe / kohorte	Intervention / Behandling
Ingen behandling Prøver som defineret i henhold til protokollen for tidligere ubehandlede patienter med AML, ALL, MDS eller MM vil blive indsendt til analyse, og inden for en måned skal patienter registreres i et CALGB-behandlingsstudie.	Genetisk: cytogenetisk analyse

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål	Tidsramme
Bestem forekomsten af specifikke mindre almindelige primære såvel som almindelige sekundære kromosomabnormaliteter i voksen AML, ALL, MDS og MM Tidsramme: Op til 10 år	Op til 10 år
Korreler specifikke (normale eller forskellige primære og sekundære kromosomale abnormiteter) med kliniske og laboratorieparametre Tidsramme: Op til 10 år	Op til 10 år
Korreler specifikke karyotypegrupper med responsrater, responsvarighed, overlevelse og helbredelse hos patienter behandlet med forskellige induktions- og postinduktionsregimer Tidsramme: Op til 10 år	Op til 10 år
Korreler specifikke karyotype grupper med udvalgte molekylære abnormiteter som undersøgt i CALGB leukæmi protokoller Tidsramme: Op til 10 år	Op til 10 år
At korrelere specifikke karyotypegrupper med multilægemiddelresistensdata Tidsramme: Op til 10 år	Op til 10 år
At korrelere specifikke karyotypegrupper med epidemiologiske data (toksisk eksponering og familiehistorie) Tidsramme: Op til 10 år	Op til 10 år
At bestemme karyotypeændringer ved tilbagefald og indflydelsen af typen af ændring (eller ingen ændring) i karyotype ved tilbagefald på det efterfølgende kliniske forløb Tidsramme: op til 10 år	op til 10 år
At identificere nye kromosomabnormiteter, der er vigtige i leukomogenese Tidsramme: Op til 10 år	Op til 10 år

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Alliance for Clinical Trials in Oncology

Samarbejdspartnere

National Cancer Institute (NCI)

Efterforskere

Studiestol: Clara Bloomfield, MD, James Cancer Hospital and Solove Research Institute

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Walker CJ, Kohlschmidt J, Eisfeld AK, Mrozek K, Liyanarachchi S, Song C, Nicolet D, Blachly JS, Bill M, Papaioannou D, Oakes CC, Giacopelli B, Genutis LK, Maharry SE, Orwick S, Archer KJ, Powell BL, Kolitz JE, Uy GL, Wang ES, Carroll AJ, Stone RM, Byrd JC, de la Chapelle A, Bloomfield CD. Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia. Clin Cancer Res. 2019 Nov 1;25(21):6524-6531. doi: 10.1158/1078-0432.CCR-19-0725. Epub 2019 Aug 2.
Mims AS, Kohlschmidt J, Borate U, Blachly JS, Orwick S, Eisfeld AK, Papaioannou D, Nicolet D, Mromicronzek K, Stein E, Bhatnagar B, Stone RM, Kolitz JE, Wang ES, Powell BL, Burd A, Levine RL, Druker BJ, Bloomfield CD, Byrd JC. A precision medicine classification for treatment of acute myeloid leukemia in older patients. J Hematol Oncol. 2021 Jun 23;14(1):96. doi: 10.1186/s13045-021-01110-5.
Sekeres MA, Peterson B, Dodge RK, Mayer RJ, Moore JO, Lee EJ, Kolitz J, Baer MR, Schiffer CA, Carroll AJ, Vardiman JW, Davey FR, Bloomfield CD, Larson RA, Stone RM; Cancer and Leukemia Group B. Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood. 2004 Jun 1;103(11):4036-42. doi: 10.1182/blood-2003-09-3118. Epub 2004 Feb 19.
Fobare S, Kohlschmidt J, Ozer HG, Mrozek K, Nicolet D, Mims AS, Garzon R, Blachly JS, Orwick S, Carroll AJ, Stone RM, Wang ES, Kolitz JE, Powell BL, Oakes CC, Eisfeld AK, Hertlein E, Byrd JC. Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia. Blood Adv. 2022 Mar 8;6(5):1371-1380. doi: 10.1182/bloodadvances.2021006242.
Marcucci G, Mrozek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA, Bloomfield CD. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005 Aug 20;23(24):5705-17. doi: 10.1200/JCO.2005.15.610.
Mrozek K, Carroll AJ, Maharry K, et al.: Central review of cytogenetics is essential for cooperative group clinical and correlative studies of acute leukemia: The Cancer and Leukemia Group B (CALGB) 8461 experience. [Abstract] Blood 104 (11): A-1081, 2004.
Baldus CD, Tanner SM, Ruppert AS, Whitman SP, Archer KJ, Marcucci G, Caligiuri MA, Carroll AJ, Vardiman JW, Powell BL, Allen SL, Moore JO, Larson RA, Kolitz JE, de la Chapelle A, Bloomfield CD. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood. 2003 Sep 1;102(5):1613-8. doi: 10.1182/blood-2003-02-0359. Epub 2003 May 15.
Heinonen K, Rao PN, Slack JL, Cruz J, Bloomfield CD, Mrozek K. Isochromosome 12p in two cases of acute myeloid leukaemia without evidence of germ cell tumour. Br J Haematol. 1996 Jun;93(3):677-80. doi: 10.1046/j.1365-2141.1996.d01-1687.x.
Cancer and Leukemia Group B 8461; Farag SS, Archer KJ, Mrozek K, Ruppert AS, Carroll AJ, Vardiman JW, Pettenati MJ, Baer MR, Qumsiyeh MB, Koduru PR, Ning Y, Mayer RJ, Stone RM, Larson RA, Bloomfield CD. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006 Jul 1;108(1):63-73. doi: 10.1182/blood-2005-11-4354. Epub 2006 Mar 7.
Farag SS, Ruppert AS, Mrozek K, Mayer RJ, Stone RM, Carroll AJ, Powell BL, Moore JO, Pettenati MJ, Koduru PR, Stamberg J, Baer MR, Block AW, Vardiman JW, Kolitz JE, Schiffer CA, Larson RA, Bloomfield CD. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol. 2005 Jan 20;23(3):482-93. doi: 10.1200/JCO.2005.06.090. Epub 2004 Nov 8.
Bloomfield CD, Ruppert AS, Mrozek K, Kolitz JE, Moore JO, Mayer RJ, Edwards CG, Sterling LJ, Vardiman JW, Carroll AJ, Pettenati MJ, Stamberg J, Byrd JC, Marcucci G, Larson RA; Cancer and Leukemia Group B (CALGB) Study 8461. Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461. Ann Hematol. 2004;83 Suppl 1:S84-5. doi: 10.1007/s00277-004-0850-2. No abstract available.
Blum W, Mrozek K, Ruppert AS, et al.: Early allogeneic transplantation for adults with de novo acute myeloid leukemia presenting with t(6;11)(q27;q23): results from CALGB 8461. [Abstract] J Clin Oncol 22 (Suppl 14): A-6543, 568s, 2004.
Blum W, Mrozek K, Ruppert AS, Carroll AJ, Rao KW, Pettenati MJ, Anastasi J, Larson RA, Bloomfield CD. Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature. Cancer. 2004 Sep 15;101(6):1420-7. doi: 10.1002/cncr.20489.
Byrd JC, Ruppert AS, Mrozek K, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Stamberg J, Koduru PR, Moore JO, Mayer RJ, Davey FR, Larson RA, Bloomfield CD. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol. 2004 Mar 15;22(6):1087-94. doi: 10.1200/JCO.2004.07.012.
Marcucci G, Mrózek, K, Ruppert AS, et al.: t(8;21) Acute myeloid leukemia (AML) differs from inv(16) AML in pretreatment characteristics, outcome and prognostic factors predicting outcome: a Cancer and Leukemia Group B (CALGB) Study. [Abstract] Blood 104 (11): A-2017, 2004.
Marcucci G, Mrozek K, Ruppert AS, Archer KJ, Pettenati MJ, Heerema NA, Carroll AJ, Koduru PR, Kolitz JE, Sterling LJ, Edwards CG, Anastasi J, Larson RA, Bloomfield CD. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. J Clin Oncol. 2004 Jun 15;22(12):2410-8. doi: 10.1200/JCO.2004.03.023.
Slovak ML, Bloomfield CD, Gundacker H, et al.: Acute myeloid leukemia (AML) with t(6;9)(p23;q34) defines a very poor risk leukemia subgroup with distinguishing clinicopathological features: a United States (US) Cytogenetics Intergroup Study of 62 AML and MDS cases. [Abstract] Blood 104 (11): A-567, 2004.
Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD; Cancer and Leukemia Group B (CALGB 8461). Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002 Dec 15;100(13):4325-36. doi: 10.1182/blood-2002-03-0772. Epub 2002 Aug 1.
Farag SS, Archer KJ, Mrozek K, Vardiman JW, Carroll AJ, Pettenati MJ, Moore JO, Kolitz JE, Mayer RJ, Stone RM, Larson RA, Bloomfield CD. Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Int J Oncol. 2002 Nov;21(5):1041-51.
Bloomfield CD, Byrd JC, Farag SS, et al.: Cytogenetics for treatment stratification in adult acute myeloid leukemia (AML). [Abstract] Ann Hematol 80 (Suppl 2): A-37, S10, 2001.
Farag SS, Archer KJ, Carroll AJ, et al.: Isolated trisomy (IT) is an adverse prognostic factor in patients (pts) with AML: results from Cancer and Leukemia Group B (CALGB 8461). [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-1124, 2001.
Marcucci G, Archer KJ, Mrózek K, et al.: Abnormal karyotype during complete remission (CR) predicts short relapse-free survival (RFS) in acute myeloid leukemia (AML): results from CALGB 8461. [Abstract] Blood 98 (11 Pt 1): A-2421, 577a, 2001.
Wetzler M, Dodge RK, Mrozek K, et al.: Secondary chromosome aberrations in adult acute lymphoblastic leukemia (ALL) with t(9;22) - a Cancer and Leukemia Group B (CALGB) study. [Abstract] Blood 98 (11 Pt 1): A-466, 111a, 2001.
Wetzler M, Dodge RK, Mrózek K, et al.: Karyotype change in adult acute myeloid leukemia (AML) at first relapse - CALGB 8461. [Abstract] Blood 96 (11 Pt 1): A-3046, 706a, 2000.
Bloomfield D: Adult acute myeloid leukemia (AML) patients (PTS) with t(8;21)(q22;q22) have a superior outcome when repetitive cycles of high-dose cytarabine (HDAC) are administered. [Abstract] Ann Hematol 78 (Suppl 2): A-50, S13, 1999.
Byrd JC, Dodge RK, Carroll A, Baer MR, Edwards C, Stamberg J, Qumsiyeh M, Moore JO, Mayer RJ, Davey F, Schiffer CA, Bloomfield CD. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999 Dec;17(12):3767-75. doi: 10.1200/JCO.1999.17.12.3767.
Wetzler M, Dodge RK, Mrozek K, Carroll AJ, Tantravahi R, Block AW, Pettenati MJ, Le Beau MM, Frankel SR, Stewart CC, Szatrowski TP, Schiffer CA, Larson RA, Bloomfield CD. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood. 1999 Jun 1;93(11):3983-93.
Baer MR, Stewart CC, Lawrence D, Arthur DC, Mrozek K, Strout MP, Davey FR, Schiffer CA, Bloomfield CD. Acute myeloid leukemia with 11q23 translocations: myelomonocytic immunophenotype by multiparameter flow cytometry. Leukemia. 1998 Mar;12(3):317-25. doi: 10.1038/sj.leu.2400933.
Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC, Mayer RJ. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998 Sep 15;58(18):4173-9.
Byrd JC, Dodge R, Carroll A, et al.: Adult acute myeloid leukemia (AML) patients (PTS) with t(8;21)(q22;q22) have a superior outcome when repetitive cycles of high-dose cytarabine (HDAC) are administered. [Abstract] Blood 92 (10 Pt 1): A-1282, 312a, 1998.
Byrd JC, Lawrence D, Arthur DC, Pettenati MJ, Tantravahi R, Qumsiyeh M, Stamberg J, Davey FR, Schiffer CA, Bloomfield CD. Patients with isolated trisomy 8 in acute myeloid leukemia are not cured with cytarabine-based chemotherapy: results from Cancer and Leukemia Group B 8461. Clin Cancer Res. 1998 May;4(5):1235-41.
Caligiuri MA, Strout MP, Lawrence D, Arthur DC, Baer MR, Yu F, Knuutila S, Mrozek K, Oberkircher AR, Marcucci G, de la Chapelle A, Elonen E, Block AW, Rao PN, Herzig GP, Powell BL, Ruutu T, Schiffer CA, Bloomfield CD. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res. 1998 Jan 1;58(1):55-9.
Heinonen K, Mrozek K, Lawrence D, Arthur DC, Pettenati MJ, Stamberg J, Qumsiyeh MB, Verma RS, MacCallum J, Schiffer CA, Bloomfield CD. Clinical characteristics of patients with de novo acute myeloid leukaemia and isolated trisomy 11: a Cancer and Leukemia Group B study. Br J Haematol. 1998 Jun;101(3):513-20. doi: 10.1046/j.1365-2141.1998.00714.x.
Wetzler M, Dodge RK, Mrózek K, et al.: Trisomy 8 represents a poor risk group in adult acute lymphoblastic leukemia (ALL): results from Cancer and Leukemia Group B (CALGB) 8461. [Abstract] Blood 92 (10 Pt 1): A-914, 223a, 1998.
Byrd JC, Weiss RB, Arthur DC, Lawrence D, Baer MR, Davey F, Trikha ES, Carroll AJ, Tantravahi R, Qumsiyeh M, Patil SR, Moore JO, Mayer RJ, Schiffer CA, Bloomfield CD. Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. J Clin Oncol. 1997 Feb;15(2):466-75. doi: 10.1200/JCO.1997.15.2.466.
Mrozek K, Heinonen K, Lawrence D, Carroll AJ, Koduru PR, Rao KW, Strout MP, Hutchison RE, Moore JO, Mayer RJ, Schiffer CA, Bloomfield CD. Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study. Blood. 1997 Dec 1;90(11):4532-8.
Bernstein SH, Brunetto VL, Davey FR, Wurster-Hill D, Mayer RJ, Stone RM, Schiffer CA, Bloomfield CD. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study. J Clin Oncol. 1996 Sep;14(9):2486-94. doi: 10.1200/JCO.1996.14.9.2486.
Byrd JC, Lawrence D, Arthur DC, et al.: Acute myeloid leukemia (AML) patients with pre-treatment isolated trisomy 8 are rarely cured with chemotherapy: results of CALGB 8461. [Abstract] Proc Am Assoc Cancer Res 37: A-1286, 188, 1996.
Caligiuri MA, Strout MP, Arthur DC, et al.: Rearrangement of ALL1 is a recurrent molecular defect in adult acute myeloid leukemia (AML) with normal cytogenetics that predicts a short complete remission (CR) duration. [Abstract] Proceedings of the American Society of Clinical Oncology 15: A-1060, 1996.
Chen H, Sandler DP, Taylor JA, Shore DL, Liu E, Bloomfield CD, Bell DA. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet. 1996 Feb 3;347(8997):295-7. doi: 10.1016/s0140-6736(96)90468-7.
Heinonen K, Mrózek K, Lawrence D, et al.: Trisomy 11 as the sole karyotypic abnormality identifies a group of older patients with acute myeloid leukemia (AML) with FAB M2 or M1 and unfavorable clinical outcome. Results of CALGB 8461. [Abstract] Proc Am Assoc Cancer Res 37: A-1275, 186-7, 1996.
Slack JL, Arthur DC, Lawrence D, Mrozek K, Mayer RJ, Davey FR, Tantravahi R, Pettenati MJ, Bigner S, Carroll AJ, Rao KW, Schiffer CA, Bloomfield CD. Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study. J Clin Oncol. 1997 May;15(5):1786-95. doi: 10.1200/JCO.1997.15.5.1786.
Niederwieser C, Nicolet D, Carroll AJ, Kolitz JE, Powell BL, Kohlschmidt J, Stone RM, Byrd JC, Mrozek K, Bloomfield CD. Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance). Haematologica. 2016 Dec;101(12):1516-1523. doi: 10.3324/haematol.2016.149542. Epub 2016 Jul 28.
Farag SS, Archer KJ, Mrózek K, et al.: Pre-treatment cytogenetics predict complete remission and long-term outcome in patients (Pts) ≥60 years with acute myeloid leukemia (AML): results from Cancer and Leukemia Group B (CALGB) 8461. [Abstract] Blood 104 (11): A-568, 2004.
Mrózek K, Heinonen K, Lawrence D, et al.: t(9;11)(p22;q23) confers better prognosis than other translocations of 11q23 in adults with de novo acute myeloid leukemia (AML): a Cancer and Leukemia Group B study. [Abstract] Cytogenet Cell Genet 77: A-P332, 136, 1997.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. juni 1984

Primær færdiggørelse (Anslået)

1. januar 2100

Datoer for studieregistrering

Først indsendt

12. november 2002

Først indsendt, der opfyldte QC-kriterier

26. januar 2003

Først opslået (Anslået)

27. januar 2003

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

31. juli 2024

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

30. juli 2024

Sidst verificeret

1. juli 2024

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

CALGB-8461
NCI-2009-00494 (Registry Identifier: CTRP (Clinical Trials Reporting Program))
CDR0000256897 (Registry Identifier: PDQ (Physician Data Query))
3U24CA114725-09S1 (U.S. NIH-bevilling/kontrakt)

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Myelomatose

Guangzhou Bio-gene Technology Co., Ltd

Trukket tilbage

BCMA/GPRC5D CAR-T-terapi til multiple myeloma

Multiple myeloma -ildfast
Zhongshan Hospital (Xiamen), Fudan University

Ikke rekrutterer endnu

Exploratory Clinical Trial of DQ1001 in Relapsed or Refractory Multiple Myeloma (RRMM)

Myelomprogression | Multiple myeloma -ildfast
University Health Network, Toronto

Rekruttering

Undersøgelse af sikkerheden og nyttigheden af liposomal kurkumin i multipelt myelom

Myelom i tilbagefald | Multiple myeloma -ildfast

Canada
Baskent University

Ikke rekrutterer endnu

Sammenligning af skrøbelighed, fysiske fitnessparametre og irisinniveauer mellem patienter med multipel sklerose og raske frivillige

MULTIPL SKLEROSE

Tyrkiet (Türkiye)
Minsk Scientific-Practical Center for Surgery,...

Rekruttering

Anti-BCMA CAR-T-celleterapi for voksne med tilbagevendende eller refraktær myelomatose (MSTH-CAR001)

Multiple myeloma -ildfast

Hviderusland
HuniLife Biotechnology, Inc.

Tilmelding efter invitation

Undersøgelse af HUL001 hos tilbagefaldte/ildfaste multiple myelomepatienter

Multiple myeloma -ildfast

Taiwan
Hebei Senlang Biotechnology Inc., Ltd.
Peking University People's Hospital; Institute of Hematology & Blood Diseases...

Ikke rekrutterer endnu

Fase I/II-studie af SENL103 til tilbagevendende eller refraktær myelomatose: Et multicentrisk, åbent, en-armet forsøg.

Myelom i tilbagefald | Multiple myeloma -ildfast
PETHEMA Foundation

Rekruttering

Effektivitet og sikkerhed af Anitocabtagene Autoleucel hos deltagere med nyligt diagnosticeret multiple myeloma (Gem-Anitofirst) (GEM-AnitoFIRST)

De novo multiple myeloma | Anitocabtagene Autoleucel

Spanien
CellCentric Ltd.

Rekruttering

Inobrodib, pomalidomid og dexamethason i tilbagefaldende eller ildfast multiple myeloma (DoMMino-1)

Myelom i tilbagefald | Multiple myeloma -ildfast

Forenede Stater, Det Forenede Kongerige
Asan Medical Center

Afsluttet

Etablering af en strategi til forebyggelse af transplantat-mod-vært-sygdom efter allogen hæmatopoietisk celletransplantation ved at undersøge immunmekanismer til regulatoriske og effektor T-celler

Akut leukæmi, myelodysplastisk syndrom, myeloproliferative neoplasmer, lymfom, multiple myeloma

Sydkorea

Kliniske forsøg med cytogenetisk analyse

Centre Médico-Chirurgical de Réadaptation des Massues...

Rekruttering

Karakterisering af synsopfattelsesforstyrrelser hos patienter med idiopatisk skoliose (EYAIS)

Idiopatisk skoliose

Frankrig
Liao Jian An

Rekruttering

Meridianenergiændringer hos patienter med hoved- og nakkekræft efter kemoterapi eller strålebehandling

Hoved- og halskræft

Taiwan
Nantes University Hospital

Ikke rekrutterer endnu

Reproducerbarhed af dental bidmærkeoverlayanalyse ved hjælp af digitale 3D-modeller hos voksne deltagere (OVERLAY-REPRO)

Rettsmedicinsk Tandlægevidenskab | Bidanalyse
Fondation Lenval

Trukket tilbage

Indflydelse af træthed på gangmønsteret hos patienter med cerebral parese.

Cerebral Parese

Frankrig
IRCCS Eugenio Medea

Afsluttet

Biomarkørers baner for tidlig intervention hos søskende til børn med autismespektrumforstyrrelse

Autismespektrumforstyrrelse | Tidlig indsats

Italien
Oregon Health and Science University
4DMedical

Tilmelding efter invitation

Ventilationsubalancer ved let til moderat kronisk obstruktiv lungesygdom (VAPOR)

Lungesygdomme | KOL | Luftvejssygdom | Dyspnø

Forenede Stater
IRCCS Eugenio Medea

Rekruttering

Bekræft præstationen i klinisk praksis af den fordybende Virtual Reality Platform GRAIL (Gait Real-time Analysis Interactive Lab)

Cerebral Parese | Erhvervet hjerneskade

Italien
Healthy.io Ltd.

Afsluttet

[Prøvning af enhed, der ikke er godkendt eller godkendt af U.S. FDA]

Albuminuri

Forenede Stater
Medwave Estudios Limitada
Asociación Chilena de Seguridad

Ukendt

Diagnostisk værdi af arbejdsbelastningsanalyseinstrument til at påvise erhvervsmæssige risici ved muskel- og skelettilstande i øvre lemmer (ACT-ACHS)

Erhvervsmæssig eksponering | Muskuloskeletal sygdom

Chile
Fundacion Clinic per a la Recerca Biomédica
Hospital Clinic of Barcelona

Rekruttering

Præcisionsmedicin til L/GCMN og melanom 1 (Precis-mel 1)

Nevi og melanomer | Melanom (hudkræft)

Spanien

Cytogenetiske undersøgelser i akut leukæmi og myelomatose

Cytogenetiske undersøgelser i akut leukæmi og multipelt myelom: ledsager til CALGB-behandlingsundersøgelser for tidligere ubehandlede patienter med akut myeloid leukæmi (AML), akut lymfoblastisk leukæmi (ALL), myelodysplastisk syndrom (MDS) eller multipelt myelom (MM)

Studieoversigt

Status

Betingelser

Intervention / Behandling

Undersøgelsestype

Tilmelding (Anslået)

Kontakter og lokationer

Studiesteder

Deltagelseskriterier

Berettigelseskriterier

Aldre berettiget til at studere

Tager imod sunde frivillige

Prøveudtagningsmetode

Studiebefolkning

Beskrivelse

Studieplan

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Antal grupper/kohorter

Kohorter og interventioner

Gruppe / kohorte

Intervention / Behandling

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål

Tidsramme

Samarbejdspartnere og efterforskere

Sponsor

Samarbejdspartnere

Efterforskere

Publikationer og nyttige links

Generelle publikationer

Datoer for undersøgelser

Studer store datoer

Studiestart (Faktiske)

Primær færdiggørelse (Anslået)

Datoer for studieregistrering

Først indsendt

Først indsendt, der opfyldte QC-kriterier

Først opslået (Anslået)

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

Sidst verificeret

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

Kliniske forsøg med Myelomatose

Kliniske forsøg med cytogenetisk analyse

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Cyprus

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer